



Published in final edited form as:

Am J Nephrol. 2012 ; 36(4): 342–347. doi:10.1159/000342794.

Carotid Plaque, Carotid Intima-Media Thickness, and Coronary Calcification Equally Discriminate Prevalent Cardiovascular Disease in Kidney Disease

Gbemisola A. Adeseun, MD[¶], Dawei Xie, PhD[†], Xin Wang, MS[†], Marshall M. Joffe, MD, MPH, PhD[†], Emile R. Mohler III, MD[‡], Raymond R. Townsend, MD^{*}, Matthew Budoff, MD[§], and Sylvia E. Rosas, MD, MSCE^{*,†,¶}

[¶] Renal Division, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California

[†] Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania

[‡] Section of Vascular Medicine, Cardiovascular Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

^{*} Renal, Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

[§] David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California

[†] Philadelphia Veterans Administration Medical Center, Philadelphia, Pennsylvania

Abstract

Background—Despite the significant morbidity and mortality attributable to cardiovascular disease (CVD), risk stratification remains an important challenge in the chronic kidney disease (CKD) population. We examined the discriminative ability of non-invasive measures of atherosclerosis, including carotid intima-media thickness (cIMT), carotid plaque, coronary artery calcification (CAC) and ascending and descending thoracic aorta calcification (TCAC), and Framingham Risk Score (FRS) to predict self-reported prevalent CVD.

Methods and Results—Participants were enrolled in the cIMT ancillary study of the Chronic Renal Insufficiency Cohort (CRIC) Study and also had all of the above measures within an 18 month period. CVD was present in 21% of study participants. C-statistics were used to ascertain the discriminatory power of each measure of atherosclerosis. The study population (n=220) was 64% male; 51% black and 45% white. The proportion of individuals with estimated glomerular filtration rate ≥ 60 , 45–59, 30–44, and <30 ml/min/1.73m² was 21%, 41%, 28%, and 11%, respectively. In multivariable analyses adjusting for demographic factors, we failed to find a difference between CAC, carotid plaque, and cIMT as predictors of self-reported prevalent CVD (c-statistic 0.70, 95% confidence interval [CI]: 0.62–0.78; c-statistic 0.68, 95% CI: 0.60–0.75, and c-statistic 0.64, CI: 0.56–0.72, respectively). CAC was statistically better than FRS. FRS was the weakest discriminator of self-reported prevalent CVD (c-statistic 0.58).

Corresponding author: Dr. Sylvia E. Rosas, Renal Electrolyte and Hypertension Division, 1st Floor Founders Building, 3400 Spruce Street, Philadelphia, PA 19104, Phone: 215-662-7934 Fax: 215-615-3447 sylvia.rosas@uphs.upenn.edu.

None of the authors have any conflicts of interest to disclose.

Disclosures

None

Conclusions—There was a significant burden of atherosclerosis among individuals with CKD, ascertained by several different imaging modalities. We were unable to find a difference in the ability of CAC, carotid plaque, and cIMT to predict self-reported prevalent CVD.

Keywords

carotid intima media thickness; coronary artery calcification; kidney; plaque

Introduction

Individuals with CKD are at extraordinarily high risk of adverse cardiovascular events.¹ The reasons for this excess cardiovascular risk are manifold and likely related to a CKD milieu that promotes vascular calcification and atherogenesis. Beyond traditional cardiovascular risk factors, such as hypertension, diabetes, and dyslipidemia, CKD is characterized by an inflammatory state that has been proposed to be an independent risk factor for atherosclerosis.² CKD is also associated with hyperphosphatemia, increased oxidative stress and a decrease in vascular calcification inhibitors, resulting in up-regulation of pathways that favor vascular smooth muscle transformation into osteoblast-like cells, resulting in vascular calcification.³

Vascular calcification is exceedingly common in CKD and can occur in the intima and/or media of blood vessels in multiple vascular beds.⁴ Vascular calcification of the media, also common in diabetes, leads to increased arterial stiffness, increased pulse wave velocity, and left ventricular hypertrophy.⁵ Alternatively, intimal vascular calcification occurs in both CKD and non-CKD population and is directly related to atherosclerosis and ischemic CVD.⁶

Noninvasive methods such as carotid ultrasound and computed tomography are used to quantify atherosclerosis and determine the presence of vascular calcification. CAC correlates with obstructive coronary artery disease in both the general and CKD population.^{7,8} CKD is a risk factor for the presence of CAC, as well as CAC progression.^{9,10} While cIMT and CAC predict adverse cardiovascular events^{11,12}, CAC is a more robust predictor of coronary events while cIMT may be a better predictor of stroke in the general population.¹³ Less is known about the predictive utility of thoracic aorta calcification and carotid plaque, which are emerging markers of increased cardiovascular risk and mortality.¹⁴

To date, no published study has compared several different measures of cardiovascular risk stratification in a population with CKD. Therefore, we assessed the ability of CAC, cIMT, carotid plaque, and ascending and descending TAC to discern prevalent CVD in CKD.

Methods

Study Design

This is a cross-sectional study of non-invasive measures of atherosclerosis as part of the cIMT ancillary study of the Chronic Renal Insufficiency Cohort (CRIC). The CRIC has been described in detail.¹⁵ In brief, the CRIC is a multi-center prospective cohort study comprised of 3939 patients with CKD, recruited from 7 centers in the United States. CRIC cIMT participants were recruited from 4 of 7 CRIC sites with expertise in cardiovascular imaging technology. Recruitment for the CRIC IMT ancillary started a year after recruitment for the main CRIC started, and participants had a carotid ultrasound performed at their convenience during any of their annual CRIC visits. CRIC participants are aged 21–74 years with an estimated glomerular filtration rate (eGFR) 20–70ml/min/1.73m² at the screening visit as calculated by the abbreviated Modification of Diet in Renal Disease

(MDRD) equation. Detailed medical histories, anthropometric and blood pressure measurements were obtained. Participants also underwent an assessment of subclinical cardiovascular disease. Individuals with a history of coronary artery bypass grafting were excluded from CT study after 2005. Two hundred and twenty participants who underwent both cIMT and CT within an 18 month time frame were included in this report. The mean time between studies was 252 days with a median of 293 days. Physiological markers such as creatinine and proteinuria were measured at each CRIC annual visit, and the results from the visit nearest to the carotid ultrasound visit were used for this analysis. Written informed consent was obtained from all study participants. The CRIC and the CRIC IMT ancillary studies were approved by the institutional review boards from each institution.

Prevalent CVD was defined as a self-reported history of myocardial infarction or revascularization, peripheral artery disease, and/or stroke. Participants were also asked to report hospitalizations during subsequent visits. Participants also had the opportunity to update their cardiovascular history during subsequent study visits, and the most up to date information regarding CVD status was used in analyses. There was no independent adjudication of the medical history obtained from participants. The FRS was based on the risk prediction model detailed by D'Agostino and colleagues.¹⁶ The calculated 10 year FRS was then categorized (<10%, 10%- <20%, and ≥20%).

Carotid Ultrasound

To ascertain cIMT and presence of carotid plaque, participants underwent carotid ultrasound. Carotid ultrasonographic images were obtained using a standardized linear array 7.5 MHz probe in the ECG-gated B mode according to standardized protocols. Interpretation of the carotid artery images was performed using an FDA approved software package (Medical Imaging Applications, Iowa City, Iowa). Using the carotid bulb as an anatomic reference, measurements were taken of the far wall of the common carotid artery as this location provides the most consistent readings, with the carotid bulb serving as an anatomic reference. A carotid plaque was defined as a focal region with CIMT >1.5 mm that protrudes into the lumen and that is distinct from the adjacent boundary.¹⁷

Computed Tomography (CT)

Participants underwent two electron-beam computed tomography (EBCT) s or multidetector CT examination for CAC and TAC quantification as previously described. EBCTs were performed on a C-150 Imatron scanner (GE, San Francisco, CA) according to established protocol. CAC was performed in a random sample who were eligible for the procedure. Approximately, a third of participants had CT. CAC, ascending thoracic aorta (TCAC), and descending TCAC were scored separately using the Agatston method. EBCTs were scored by a single reader for consistency. The EBCT score that was closest in proximity to the carotid ultrasound examination was used for analyses.

Statistical Analysis

Descriptive statistics were performed using means with standard deviation and medians with interquartile ranges for continuous variables and proportions for categorical variables.

The distribution of cIMT, plaque, CAC, ascending TCAC, and descending TCAC were not normally distributed and thus were analyzed as categorical variables. A substantial portion of individuals had no ascending or descending thoracic aorta calcification, so these variables were categorized thus: 0, 1 to < median, and ≥ median. CAC was categorized as follows: 0, 1 - <100, 100 - <400, ≥400 Agatston units.

To assess the degree of variance in the prevalence of CVD that can be explained by the presence of traditional atherosclerotic risk factors in the study population and in subgroups defined above, the discriminative power of the models was assessed using the c-statistics and their 95% confidence intervals obtained using bootstrapping techniques. A multivariate logistic regression model including demographic variables (age, gender, and race) to obtain an adjusted c-statistic was performed. The statistical software package SAS version 9.2 was used for all analyses (SAS Institute, Inc, Cary, NC).

Results

Demographic and comorbidity data is presented in Table 1. The average age was 61.6 years, with a predominance of men (64%). Approximately half of the study population was black. Although the self-reported prevalence of CVD was 20%, risk factors for CVD were common with hypertension and diabetes affecting 90% and 55% of the population, respectively. The metabolic syndrome was present in 55% of participants, a marker of increased CVD risk. Unadjusted analyses revealed a statistically significant association between eGFR with CAC and cIMT (Supplemental Table 1).

We found that several subclinical measures had increased values as the CAC scores increased in participants without self-reported CVD (Table 2). This was more evident with carotid plaque and descending TAC.

In unadjusted analyses, the ability of CAC, carotid plaque, and cIMT to discriminate prevalent CVD were comparable with c-statistics of 0.67, 0.64 and 0.61, respectively ($p > 0.05$). Ascending and descending thoracic aortic calcifications with c-statistics of 0.54 and 0.57, respectively. The FRS has been validated in the general population but had marginal discriminatory value in this setting, with a c-statistic of only 0.56 (Table 3). After adjusting for age, gender, and race in multivariable logistic regression analyses, the discriminatory power of each measure of CVD risk improved. CAC appeared to be the best predictor of self-reported prevalent CVD followed by carotid plaque, with c-statistics of the adjusted models 0.70 and 0.68, respectively. The c-statistics for ascending and descending TAC also improved modestly. FRS was the least discriminatory (c-statistic 0.58). Differences between CAC, carotid plaque, and cIMT were not statistically significant.

Discussion

This study evaluates different measures of cardiovascular risk stratification including CAC, ascending and descending TCAC, cIMT, carotid plaque, and the FRS in a diverse cohort of individuals with CKD. Using these different imaging modalities, we identified a high burden of atherosclerosis among individuals with CKD. Of the non-invasive direct measures of atherosclerosis, we were unable to detect any statistical difference between CAC and carotid plaque or cIMT as predictors of self-reported prevalent CVD.

Non-invasive measures of atherosclerosis are increasingly used in the CKD population for cardiovascular risk stratification.¹⁸ It is postulated that both traditional and non-traditional risk factors contribute to the early and extensive CAC that has been observed among individuals with CKD.¹⁰ CAC has several advantages which include an established algorithm, wide availability and lack of dependence on the operator. Measurement of cIMT, on the other hand, is operator dependent and requires specialized equipment and training. In the Multiethnic Study of Atherosclerosis in individuals without self-reported CVD, CAC was superior to cIMT for prediction of any incident CVD or any coronary event.¹³ However in the same study, cIMT was a better predictor of stroke. Prospective data regarding the role of non-invasive measures of atherosclerosis and cardiovascular risk stratification are limited

in the non-dialysis dependent CKD population. There is evidence that there is a direct correlation between CAC score and obstructive luminal lesions within coronary arteries in patients with CKD.⁸ CAC is superior to IMT in predicting self-reported prevalent CVD identified by coronary angiography.¹⁹ Further, CAC is associated with increased cardiovascular events and hospitalizations.¹⁸ Although we found that CAC is associated with the highest index of discrimination for self-reported prevalent CVD which improved with the inclusion of demographic variables, we were unable to find a statistical difference with the other subclinical measures to predict self-reported prevalent CVD in our population. This improvement after adjustment reflects confounding by age, gender, and race, variables that have been associated with CAC in other studies.⁹

We did not find a statistically significant difference in the discriminative power of CAC, carotid plaque, and cIMT. Prior research has shown that carotid plaque and cIMT are highly correlated, and each independently predicts cardiovascular events in non-CKD cohorts.²⁰ To date, there are no studies in the CKD population that compare cIMT and plaque prediction of CVD, although the CRIC study is poised to address this question in the future. A prospective study of individuals with ESRD found that carotid plaque progression, and not IMT, was an important predictor of cardiovascular events suggesting that plaque is a more sensitive measure of atherosclerosis than cIMT.²¹ In our study, we found that the c-statistic for carotid plaque was higher than that of cIMT in both univariable and multivariable analyses, however, this difference was not statistically significant. We may not have been sufficiently powered to detect a difference between carotid plaque and IMT. Nonetheless, our results indicate that the use of carotid plaque and cIMT would be reasonable alternatives to CAC. There is increasing concern about the use of radiation with CT. Therefore, our results demonstrate that carotid ultrasound may be a reasonable alternative. In addition, particularly in younger individuals (20–30 years) who typically do not have calcification, carotid ultrasound is likely the more appropriate subclinical cardiovascular tool.

Aortic arch calcification (AAC) is prevalent in CKD¹⁸ and presence of AAC is associated with other markers of increased cardiovascular risk.²² We found that neither ascending nor descending aortic calcification was a strong predictor of self-reported prevalent CVD in unadjusted analyses with only mild improvement in predictive power with multivariable analyses.

In addition to non-invasive measures of atherosclerosis, clinical cardiovascular risk prediction tools such as the FRS can be an effective means of cardiovascular risk stratification in the general population. In our study population, the FRS was marginally associated with self-reported prevalent CVD. Weiner and colleagues have previously described a similar c-statistic for incident cardiovascular events predicted by the FRS among men in a CKD cohort (10 year c-statistics 0.60 and 0.73 for men and women, respectively).²³ In comparison, our study population was comprised of significantly more diabetic participants and a higher proportion of blacks, which may account for the difference. Adjusting for demographic variables did not have a significant impact on the c-statistic, likely because both age and gender are included in the Framingham risk calculation.

There are important limitations of this study. First, we relied on participant self-report of CVD, which may have introduced misclassification bias. It is well known that several factors impact patient knowledge of CVD. Patients may underestimate or overestimate their degree of cardiovascular risk.²⁴ Lack of knowledge about co-morbidities has been associated with increased mortality in a dialysis cohort.²⁵ Misclassification bias may also be present as a result of the possible lag between determination of prevalent CVD and subsequent cardiovascular imaging. Second, our study was performed in a subset of CRIC

clinical sites and therefore the sample size is limited. The results of this study may not be generalizable to other populations. Participants in the CRIC study are not representative of the general CKD population. Study participants were predominantly male with predominantly stage 3 CKD, relative low level of proteinuria and good blood pressure control. Thus, selection bias may have resulted in enrollment of a comparatively healthier subset of individuals with CKD, limiting the generalizability of our findings. Finally, we are not able to evaluate the predictive utility of each of these tests in measuring incident cardiovascular events due to limited follow up.

In conclusion, subclinical cardiovascular measures identify a significant burden of disease in CKD. CAC appears to be the best predictor of self-reported prevalent CVD. However, no statistical difference was found with cIMT or carotid plaque. Carotid plaque and cIMT are appealing in that radiation is not required to obtain these measures. Given the technical expertise required to obtain IMT, presence of carotid plaque is emerging as an important tool for cardiovascular risk stratification in CKD. Prospective studies such as CRIC will allow us to determine the predictive value of these risk assessment tools for incident cardiovascular events and mortality.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank all participants and investigators of the CRIC Study for their contributions.

Funding Sources

GA was supported by a research supplement to S.E.R.'s National Institutes of Health (NIH) grant R01 DK080033. S.E.R. was supported by NIH grant DK-064343 and R01 DK080033 from the National Institute of Diabetes and Digestive and Kidney Diseases and by the Department of Veterans Affairs (HSR &D IIR 05-247).

Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by: the University of Pennsylvania CTSC CTSA UL1 RR-024134, Johns Hopkins University UL1 RR-025005, Michigan Institute for Clinical and Health Research (MICHR) UL1RR024986, and The Clinical and Translational Research, Education, and Commercialization Project (CTRECP).

References

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis.* 1998; 32:S112–S119. [PubMed: 9820470]
2. Lemos MM, Jancikic AD, Sanches FM, et al. Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease. *Nephron Clinical practice.* 2010; 115:c189–C194. [PubMed: 20413996]
3. Giachelli CM. The emerging role of phosphate in vascular calcification. *Kidney Int.* 2009; 75:890–897. [PubMed: 19145240]
4. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant.* 2003; 18:1731–1740. [PubMed: 12937218]
5. Chen NX, Moe SM. Arterial calcification in diabetes. *Current diabetes reports.* 2003; 3:28–32. [PubMed: 12643143]
6. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. *Clin J Am Soc Nephrol.* 2009; 4:1892–1900. [PubMed: 19833908]

7. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). *Circulation*. 2007; 115:402–426. [PubMed: 17220398]
8. Robinson J, Tan AU, Wilensky RL, Matthai W, Munoz M, Rosas SE. Electron-beam computerized tomography correlates with coronary angiogram in chronic kidney disease patients. *Am J Nephrol*. 2007; 27:247–252. [PubMed: 17389785]
9. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS. Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. *Kidney Int*. 2009; 76:991–998. [PubMed: 19692998]
10. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. *J Am Soc Nephrol*. 2005; 16:507–513. [PubMed: 15601745]
11. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. *Annals of internal medicine*. 1998; 128:262–269. [PubMed: 9471928]
12. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. *American journal of epidemiology*. 1997; 146:483–494. [PubMed: 9290509]
13. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). *Arch Intern Med*. 2008; 168:1333–1339. [PubMed: 18574091]
14. Rundek T, Arif H, Boden-Albala B, Elkind MS, Paik MC, Sacco RL. Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. *Neurology*. 2008; 70:1200–1207. [PubMed: 18354078]
15. Feldman HI, Appel LJ, Chertow GM, et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. *J Am Soc Nephrol*. 2003; 14:S148–S153. [PubMed: 12819321]
16. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008; 117:743–753. [PubMed: 18212285]
17. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim intima-media thickness consensus. *Cerebrovasc Dis*. 2004; 18:346–349. [PubMed: 15523176]
18. Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. *Clin J Am Soc Nephrol*. 5:189–194. [PubMed: 19965535]
19. Terry JG, Carr JJ, Tang R, et al. Coronary artery calcium outperforms carotid artery intima-media thickness as a noninvasive index of prevalent coronary artery stenosis. *Arterioscler Thromb Vasc Biol*. 2005; 25:1723–1728. [PubMed: 15947237]
20. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation*. 1997; 96:1432–1437. [PubMed: 9315528]
21. Benedetto FA, Tripepi G, Mallamaci F, Zoccali C. Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD. *J Am Soc Nephrol*. 2008; 19:757–763. [PubMed: 18184855]
22. Iijima K, Hashimoto H, Hashimoto M, et al. Aortic arch calcification detectable on chest X-ray is a strong independent predictor of cardiovascular events beyond traditional risk factors. *Atherosclerosis*. 210:137–144. [PubMed: 20006335]
23. Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. *J Am Coll Cardiol*. 2007; 50:217–224. [PubMed: 17631213]
24. Englert H, Muller-Nordhorn J, Seewald S, et al. Is patient self-report an adequate tool for monitoring cardiovascular conditions in patients with hypercholesterolemia? *J Public Health (Oxf)*. 2010; 32:387–394. [PubMed: 20208067]

25. Cavanaugh KL, Merkin SS, Plantinga LC, Fink NE, Sadler JH, Powe NR. Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD. *Am J Kidney Dis.* 2008; 52:118–127. [PubMed: 18589216]

\$watermark-text

\$watermark-text

\$watermark-text

Table 1

Variable	Coronary Artery Calcification			
	0 (n=63)	0-<100 (n=57)	100-<400 (n=41)	400 (n=59)
Carotid plaque	Mean(s.d.) 0.6 (1.2)	0.7 (1.1)	1.3 (1.4)	2.3 (1.8)
	Median (P25- P75) 0.0 (0.0 – 1.0)	0.0 (0.0 – 1.0)	1.0 (0.0 – 2.0)	2.0 (0.0 – 4.0)
Carotid Intima Media Thickness	Mean(s.d.) 0.7 (0.1)	0.8 (0.2)	0.8 (0.2)	0.8 (0.2)
	Median (P25- P75) 0.7 (0.6 – 0.8)	0.8 (0.7 – 0.9)	0.8 (0.6 – 0.9)	0.8 (0.7 – 1.0)
Ascending Thoracic Aortic Calcification	Mean(s.d.) 1.7 (12.3)	46.4 (263.9)	15.8 (59.0)	26.4 (96.8)
	Median (P25- P75) 0.0 (0.0 – 0.0)	0.0 (0.0 – 0.0)	0.0 (0.0 – 0.0)	0.0 (0.0 – 0.0)
Descending Thoracic Aortic Calcification	Mean(s.d.) 60.2 (246.7)	89.8 (246.8)	382.0 (578.1)	831.5 (2106.6)
	Median (P25- P75) 0.0 (0.0 – 0.0)	0.0 (0.0 – 53.3)	80.3 (0.0 – 757.4)	75.6 (0.0 – 678.3)
10 year Framingham Risk	Mean(s.d.) 12.4 (8.6)	19.2 (9.5)	21.4 (9.0)	23.2 (7.5)
	Median (P25- P75) 11.2 (4.7 – 18.4)	18.5 (11.2 – 30.0)	24.8 (13.7 – 30.0)	25.3 (18.4 – 30.0)

Table 2

Measurement	Unadjusted C-statistic	CI	Adjusted C-statistic*	CI
Coronary Artery Calcification	0.67	0.59–0.76	0.70	0.62–0.78
Carotid plaque	0.64	0.56–0.73	0.68	0.60–0.75
Carotid Intima Media Thickness	0.61	0.53–0.69	0.63	0.55–0.71
Ascending Thoracic Aortic Calcification	0.54	0.49–0.59	0.64	0.56–0.71
Descending Thoracic Aortic Calcification	0.57	0.49–0.66	0.61	0.52–0.69
10 year Framingham Risk	0.56	0.47–0.66	0.58	0.47–0.68

* Adjusted for age, gender, and race